• Explore /
  • Poster
  • / Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).

Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).

Abstract Video & Slides Poster

Authors

null

Tara L. Lin

University of Kansas Medical Center, Kansas City, KS

Tara L. Lin , Geoffrey L. Uy , Roland B. Walter , Heng Zou , Qi Wang , Stefan Faderl , Ronald Cheung , Vinod A. Pullarkat

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT04038437

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS7567)

DOI

10.1200/JCO.2020.38.15_suppl.TPS7567

Abstract #

TPS7567

Poster Bd #

340

Abstract Disclosures

Similar Posters

First Author: Geoffrey L. Uy

First Author: Vinod Pullarkat

First Author: Amer Methqal Zeidan

First Author: James K. McCloskey